Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30595% above fair value
$228.44+7.61 (+3.45%)
Close on Nov 3, 2026Market cap $91.20BP/E –Yield –
Moderna GTN provision by Quarter
GTN provision — Chargebacks, discounts and distribution fees ($M) ($M)
Moderna GTN provision: $50M in Q2 2026, down 19.4% from a year earlier.
Latest, Q2 2026
50
Period ended Jun 30, 2026
Change on a year earlier
-19.4%
62 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
11
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Gross-to-Net Rollforward).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GTN provision — Chargebacks, discounts and distribution fees ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 50 | -19.4% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | -11 | -150.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 191 | +117.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 762 | -27.6% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 62 | -381.8% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 22 | 0.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 88 | -82.3% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,053 | +119.8% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | -22 | – | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 22 | – | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 497 | – | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 479 | – | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | – | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 0 | – | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 0 | – | Form 10-Q (filed 2023-11-03) ↗ |
Cite this data
StockData. (2026). Moderna GTN provision ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/gtn-prov-chargebacks
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.
See a number that looks wrong?